Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 15, 2024

FogPharma and ARTBIO collaborate to co-develop new cancer therapies

FogPharma has partnered with ARTBIO to co-develop Helicon-enabled alpha radioligand therapies (HEARTs), a new class of treatments aimed at improving outcomes for cancer patients.

Continue
The two partners will contribute equally to the research, development, and commercialisation phases of the collaboration. Credit: Tatiana from Pixabay.
May 14, 2024

PharmaLogic launches new radiopharmaceutical facility in New York, US

The new facility is aimed at enhancing radiopharmaceutical development of the company. Credit: PharmaLogic.
May 10, 2024

Aardvark Therapeutics secures $85m in Series C funding round

The company plans to allocate the Series C funds primarily towards concluding the clinical trials. Credit: National Cancer Institute on Unsplash.

Contracts

December 14, 2022

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Micrograph of psoriasis vulgaris. Credit: Jenny Giang, Marc A. J. Seelen, Martijn B. A. van Doorn, Robert Rissmann,Errol P. Prens and Jeffrey Damman/ commons.wikimedia.org.

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Kite, Refuge sign license deal for gene expression platform for blood cancers

Deals

Deals April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Pharmaceutical Business Review

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Kindeva Drug Delivery acquires Summit Biosciences

Popular

  1. IMA Life to build new pharma freeze-drying equipment production site
  2. ImmunoACT and Caring Cross sign TriCAR-T cell therapy development deal
  3. OverT Bio secures $16m in seed funding for cell therapy development
  4. FDA accepts BLA for BMS’ subcutaneous nivolumab to treat solid tumours
  5. Latus Bio secures $54m for CNS gene therapy development

PRESS RELEASES

Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Gerresheimer Performance Levels Simplify Choice of Optimum Solution
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Sofgen Pharmaceuticals to Exhibit at CPhI North America 2024
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Molnar Institute at Analytica 2024 – 9-12 April in Munich, Germany
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK
Butterworth at Making Pharmaceuticals 2024 – 23-24 April in Coventry, UK

Suppliers

Whitepapers

Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Topicals – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation
Oral Formulations – Selecting the Right Antiseptic for Your Formulation